The Simcyp Population-based Simulator streamlines drug development through the modeling and simulation of pharmacokinetics and pharmacodynamics in virtual populations. The Simcyp Simulator is the pharmaceutical industry’s most sophisticated platform for the prediction of drug-drug interactions and pharmacokinetic outcomes in clinical populations.
The Cardiac Safety Simulator™ (CSS) is a systems biologydriven, modeling and simulation-based platform for the assessment of the pro-arrhythmic potency of drugs, new chemical entities, and other xenobiotics within the targeted clinical population.
Simcyp grants academic licenses for the Simcyp Simulator to centers of excellence in research related to drug development. Academic license agreements differ from Consortium member contracts to reflect the not-for-profit nature of the research. This makes them more accessible to scientists on non-commercial budgets.
Certara is a global biosimulation and regulatory writing company that uses modeling and simulation technology to inform and optimize the most crucial drug development decisions. The company has amassed the most scientifically advanced modeling and simulation approaches and aligned them with proven regulatory strategies to increase R&D productivity and the probability of commercial success for our clients.
• Quantifying clinical trial efficacy, tolerability, and safety information to enable informed drug development decisions
• Incorporating quantitative pharmacology models for the effects of treatment, time, and patient characteristics on therapeutic outcome
• Competitive positioning, quantitative definition of Best-in-Class, assessment of drug class characteristics, and optimizing clinical trial designs
Certara® is a leading drug development and drug safety consultancy trusted by thousands of biopharmaceutical companies worldwide. Offering a broad range of scientific consulting services and software solutions, from early drug discovery, to clinical development through product commercialization, Certara is the most comprehensive single-source solutions provider in the market.
MBMA uses highly curated clinical trial data and pharmacology models to increase drug development productivity, quantitatively inform portfolio management, and improve clinical trial success.
Certara, the global leader in modeling and simulation, offers service focused on delivering greater precision and expanded populations in drug labels through proven methodology.
Now the largest and most comprehensive model-based drug development and strategic pharmacometrics organization, Certara Strategic Consulting brings together the resources of Certara’s leading consulting group, Pharsight Consulting Services (PCS) with scientific powerhouse Quantitative Solutions Inc.